Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.53 |
| ▸ | CCND1 | P24385 | 17/20 | 0.53 |
| ▸ | CCND2 | P30279 | 17/20 | 0.53 |
| ▸ | CCND3 | P30281 | 17/20 | 0.53 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.52 |
| ▸ | MARK3 | P27448 | 1/20 | 0.52 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.52 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.52 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.52 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507738 | 1.00 | CDK4 (0.53) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL30878784 | 0.86 | CDK4 (0.41) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL1226050 | 0.86 | CDK4 (0.41) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL7076399 | 0.86 | CDK4 (0.52) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL1227335 | 0.86 | CDK4 (0.41) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL1227255 | 0.86 | CDK4 (0.41) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL1226546 | 0.86 | CDK4 (0.41) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL1227274 | 0.85 | CDK4 (0.42) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL1226187 | 0.85 | CDK4 (0.42) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL22585849 | 0.84 | CDK4 (0.40) | CDK4CCND1CCND2CCND3NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042936-A1 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (F.S.P. CNIO) (ES) | 2023-02-09 | — | — | US | disclosed |
| WO-2021183994-A1 | PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | PROSENESTAR LLC (US) | 2021-09-16 | — | — | WO | disclosed |
| CN-106632313-B | Important intermediate of anticancer drug palbociclib and synthesis process | 上海贤鼎生物科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-3718560-A2 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | The University of North Carolina at Chapel Hill (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3406260-B1 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3025724-B1 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9808461-B2 | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808461-B2 | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060047118-A1 | New pteridinones as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1268476-A1 | 5-ALKYLPYRIDO[2,3-D]PYRIMIDINES TYROSINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070741-A1 | 5-ALKYLPYRIDO[2,3-D]PYRIMIDINES TYROSINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CDK4 1/4885CCND1 27/4885CCND2 33/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CDK4 3/4885CCND1 73/4885CCND2 51/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CDK4 1/4885CCND1 34/4885CCND2 35/4885 |
| US-20230042936-A1 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | CDK7, CDK8, CDK9 | CDK4 7/4885CCND1 35/4885CCND2 38/4885 |
| US-20060047118-A1 | New pteridinones as PLK inhibitors | PLK2, PLK4, PLK3 | CDK4 42/4885CCND1 24/4885CCND2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.